| First Author | Singulani MP | Year | 2020 |
| Journal | Exp Gerontol | Volume | 133 |
| Pages | 110882 | PubMed ID | 32084533 |
| Mgi Jnum | J:311344 | Mgi Id | MGI:6718022 |
| Doi | 10.1016/j.exger.2020.110882 | Citation | Singulani MP, et al. (2020) Impairment of PGC-1alpha-mediated mitochondrial biogenesis precedes mitochondrial dysfunction and Alzheimer's pathology in the 3xTg mouse model of Alzheimer's disease. Exp Gerontol 133:110882 |
| abstractText | Impairment of mitochondrial biogenesis and mitochondrial dysfunction is a prominent feature of Alzheimer's disease (AD). However, the extent to which the impairment of mitochondrial biogenesis influences mitochondrial dysfunction at the onset and during progression of AD is still unclear. Our study demonstrated that the protein expression pattern of the transcription factor pCREB/CREB, together with the protein expression of PGC-1alpha, NRF1 and TFAM are all significantly reduced in early ages of 3xTg-AD mice. We also found reduced mRNA expression levels of PKAC-alpha, CREB, PGC-1alpha, NRF1, NRF2 and TFAM as early as 1 month-of-age, an age at which there was no significant Abeta oligomer deposition, suggesting that mitochondrial biogenesis is likely impaired in ages preceding the development of the AD pathology. In addition, there was a decrease in VDAC2 expression, which is related to mitochondrial content and mitochondrial function, as demonstrated by protein expression of complex IV, as well as complex II + III, and complex IV activities, at later ages in 3xTg-AD mice. These results suggest that the impairment in mitochondrial biogenesis signaling mediated by PGC-1alpha at early ages of the AD mice model likely resulted in mitochondrial dysfunction and manifestation of the AD pathology at later ages. Taken together, enhancing mitochondrial biogenesis may represent a potential pharmacological approach for the treatment of AD. |
